Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$16B
P/E ratio
11× (adj.)
Div yield
—
EPS (TTM)
$23 (adj.)
Profit margin
33% (adj.)
Rev. growth
+5%
Revenue
$4.3B
Free cash flow
$1.3B
In plain English
Jazz is an Irish-domiciled specialty pharma built on two pillars: a neuroscience franchise (the oxybate sleep drugs Xywav/Xyrem and the cannabidiol epilepsy drug Epidiolex, bought with GW Pharmaceuticals for $7.2B) and a growing oncology business (Rylaze, Zepzelca, Defitelio, Vyxeos, Ziihera). It made ~$4.3B in 2025 revenue but posted a GAAP loss after a write-off on its Chimerix deal — the business is highly cash-generative on an adjusted basis.
In simple terms
What Jazz Pharmaceuticals plc really sells
Jazz is an Irish-domiciled specialty pharma built on two pillars: a neuroscience franchise (the oxybate sleep drugs Xywav/Xyrem and the cannabidiol epilepsy drug Epidiolex, bought with GW Pharmaceuticals for $7.2B) and a growing oncology business (Rylaze, Zepzelca, Defitelio, Vyxeos, Ziihera). It made ~$4.3B in 2025 revenue but posted a GAAP loss after a write-off on its Chimerix deal — the business is highly cash-generative on an adjusted basis.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.